Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration

Further Publications

Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration

Eur J Cancer.

Pearson AD, Stegmaier K, Bourdeaut F, Reaman G, Heenen D, Meyers ML, Armstrong SA, Brown P, De Carvalho D, Jabado N, Marshall L, Rivera M, Smith M, Adamson PC, Barone A, Baumann C, Blackman S, Buenger V, Donoghue M, Duncan AD, Fox E, Gadbaw B, Hattersley M, Ho P, Jacobs I, Kelly MJ, Kieran M, Lesa G, Ligas F, Ludwinski D, McDonough J, Nikolova Z, Norga K, Senderowicz A, Taube T, Weiner S, Karres D, Vassal G

doi: 10.1016/j.ejca.2020.08.014.

Risk-stratified staging in paediatric hepatoblastoma: a unified analysis from the Children's Hepatic tumors International Collaboration

Lancet Oncol.

Meyers RL, Maibach R, Hiyama E, Häberle B, Krailo M, Rangaswami A, Aronson DC, Malogolowkin MH, Perilongo G, von Schweinitz D, Ansari M, Lopez-Terrada D, Tanaka Y, Alaggio R, Leuschner I, Hishiki T, Schmid I, Watanabe K, Yoshimura K, Feng Y, Rinaldi E, Saraceno D, Derosa M, Czauderna P

Further Publications

Precision Oncology and Gender Medicine – Moving Forward, Slowly but Surely

healthbook TIMES Oncology Hematology

1Department of Oncology, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), CH-1011, Switzerland 2International Cancer Prevention Institute, Epalinges, CH-1066, Switzerland *corresponding authors

Accelerating anticancer drug development - opportunities and trade-offs

Nat Rev Clin Oncol.

Nass SJ, Rothenberg ML, Pentz R, Hricak H, Abernethy A, Anderson K, Gee AW, Harvey RD, Piantadosi S, Bertagnolli MM, Schrag D, Schilsky RL

doi: 10.1038/s41571-018-0102-3.

Gastrointestinal CancerFurther Publications

Targeting the Tumor in Colorectal Cancer – Where do we Stand with Precision Medicine in 2020

★ 3 Recommended and commented by Alexander Meisel, Faculty Member

healthbook TIMES Oncology Hematology

Corresponding author: Dr Alexander Siebenhüner Senior Consultant in Medical Oncology Cantonal Hospital Schaffhausen Schaffhausen, Switzerland

Further Publications

Clinical implications of food-drug interactions with small-molecule kinase inhibitors

Lancet Oncol.

Veerman GDM, Hussaarts KGAM, Jansman FGA, Koolen SWL, van Leeuwen RWF, Mathijssen RHJ

doi: 10.1016/S1470-2045(20)30069-3.

Lung Cancer

Molecular Diagnostic and Precision Medicine in Non-Small Cell Lung Cancer. An Update on the Treatment of the Most Important Actionable Oncogenic Driver Alterations.

1Department of Medical Oncology, University Hospital Basel, Basel, Switzerland.

Lymphoma

The CAR T Cell Story

healthbook TIMES Oncology Hematology

Russkamp N., Zenz T.

doi: 10.36000/hbT.OH.2019.01.001

Further Publications

Development of paediatric non-stage prognosticator guidelines for population-based cancer registries and updates to the 2014 Toronto Paediatric Cancer Stage Guidelines

Lancet Oncol.

Gupta S, Aitken J, Bartels U, Bhakta N, Bucurenci M, Brierley JD, De Camargo B, Chokunonga E, Clymer J, Coza D, Fraser C, Fuentes-Alabi S, Gatta G, Gross T, Jakab Z, Kohler B, Kutluk T, Moreno F, Nakata K, Nur S, Parkin DM, Penberthy L, Pole J, Poynter JN, Pritchard-Jones K, Ramirez O, Renner L, Steliarova-Foucher E, Sullivan M, Swaminathan R, Van Eycken L, Vora T, Frazier AL

doi: 10.1016/S1470-2045(20)30320-X.

Related content

Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration

Risk-stratified staging in paediatric hepatoblastoma: a unified analysis from the Children's Hepatic tumors International Collaboration

Precision Oncology and Gender Medicine – Moving Forward, Slowly but Surely

Accelerating anticancer drug development - opportunities and trade-offs

Targeting the Tumor in Colorectal Cancer – Where do we Stand with Precision Medicine in 2020

Clinical implications of food-drug interactions with small-molecule kinase inhibitors

Molecular Diagnostic and Precision Medicine in Non-Small Cell Lung Cancer. An Update on the Treatment of the Most Important Actionable Oncogenic Driver Alterations.

The CAR T Cell Story

Development of paediatric non-stage prognosticator guidelines for population-based cancer registries and updates to the 2014 Toronto Paediatric Cancer Stage Guidelines